Neogen Chemicals Beheer
Beheer criteriumcontroles 4/4
De CEO Neogen Chemicals is Harin Kanani, benoemd in Oct2025, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 13.75M, bestaande uit 99.6% salaris en 0.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 12.2% van de aandelen van het bedrijf, ter waarde ₹ 7.54B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7.9 jaar.
Belangrijke informatie
Harin Kanani
Algemeen directeur
₹13.8m
Totale compensatie
| Percentage CEO-salaris | 99.64% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 12.2% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 7.9yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Aug 25
NEOGEN: Animal And Food Safety Upswing Will Support Long Term Upside
Analysts have lifted their fair value estimate for Neogen Chemicals to ₹2,501 from ₹2,310, citing updated assumptions on revenue growth, profit margins, discount rate and future P/E that reflect a more supportive backdrop for its animal safety and food safety segments. What’s in the News for Neogen Chemicals Neogen Chemicals has scheduled a board meeting on Jul 24, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.
Narratiefupdate • Aug 11
NEOGEN: Elevated Future P E Will Persist Despite Lower Margin Assumptions
Analysts have raised their fair value estimate for Neogen Chemicals from ₹1,455 to about ₹1,584, citing updated assumptions on growth, margins, discount rate and future P/E based on recent research commentary around a better animal safety backdrop and improving food safety efficiencies. What’s in the News for Neogen Chemicals Neogen Chemicals has scheduled a board meeting on Jul 24, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.Analyse-artikel • Jul 29
Neogen Chemicals Limited Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next
A week ago, Neogen Chemicals Limited ( NSE:NEOGEN ) came out with a strong set of quarterly numbers that could...
Narratiefupdate • Jul 28
NEOGEN: Rich P/E And Higher Margin Outlook Will Shape Balanced Returns
Analysts have raised the price target for Neogen Chemicals from ₹1,924 to ₹2,167, citing updated assumptions on revenue growth, profit margin, and future P/E that feed into their valuation models. What’s in the News for Neogen Chemicals A board meeting is scheduled for May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, and to consider a possible final dividend recommendation on equity shares, subject to shareholder approval at the 37th AGM.Narratiefupdate • Jul 14
NEOGEN: Rich P/E And Lower Margin Outlook Will Pressure Future Returns
Analysts have revised their price target for Neogen Chemicals from ₹1,756.25 to ₹1,924.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that collectively change their valuation framework. What’s in the News for Neogen Chemicals A board meeting is scheduled on April 18, 2026 to consider the allotment of 1,000,000 equity shares of face value ₹10 each at ₹1,610 per share, including a premium of ₹1,600 per share, aggregating to ₹161,00,00,000 on a preferential basis to a specified allottee.Narratiefupdate • Jun 16
NEOGEN: Preferential Share Issue Will Keep Future P E Excessively Elevated
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,455, citing relatively unchanged assumptions around revenue growth, profit margins and future P/E multiples, along with a slightly lower discount rate that fine tunes but does not materially shift their overall price target view. What’s in the News for Neogen Chemicals A board meeting is scheduled on May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend recommendation for approval at the 37th AGM.Narratiefupdate • Jun 02
NEOGEN: Preferential Equity Issue Will Sustain Pressure On Elevated Future P E
Analysts have raised their price target on Neogen Chemicals from ₹1,335 to ₹1,455, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider recommending a final dividend on equity shares, subject to shareholder approval at the 37th AGM.Analyse-artikel • May 24
Neogen Chemicals' (NSE:NEOGEN) Problems Go Beyond Weak Profit
The market wasn't impressed with the soft earnings from Neogen Chemicals Limited ( NSE:NEOGEN ) recently. We did some...Narratiefupdate • May 11
NEOGEN: Preferential Equity Funding Will Support Long Term Upside Potential
Analysts have trimmed their price target for Neogen Chemicals from ₹2,630 to about ₹2,311 as they factor in more moderate revenue growth assumptions, a slightly higher profit margin outlook, and a lower future P/E multiple in their models. What's in the News Board meeting scheduled for April 18, 2026, to consider allotment of 1,000,000 equity shares with face value of ₹10 at an issue price of ₹1,610 per share on a preferential basis, aggregating up to ₹1,610,000,000.Narratiefupdate • Apr 23
NEOGEN: Equity Fundraising Plans Will Pressure Elevated Future P E Multiple
Analysts have kept their price target for Neogen Chemicals steady at ₹1,335, citing only small refinements to their discount rate, revenue growth outlook and profit margin assumptions, along with a slightly lower future P/E multiple, rather than any major shift in the investment case. What's in the News On February 11, 2026, the board met to review unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, and to evaluate various options for raising funds through equity and other securities in one or more tranches (company filing).Narratiefupdate • Apr 09
NEOGEN: Future PE Reset Will Test Sustainability Of Recent Cost Improvements
Narrative Update Analysts have held the fair value estimate for Neogen Chemicals steady at ₹1,335.00 while updating assumptions on growth, margins and future P/E. This reflects recent research that cites stronger revenue and EBITDA performance, cost actions taking hold and higher external price targets in the range of roughly ₹540 to ₹1,000 equivalent.Narratiefupdate • Mar 25
NEOGEN: Raised Guidance And Cost Actions Will Support Higher Future Earnings Quality
Narrative Update Overview The revised analyst price target for Neogen Chemicals edges slightly lower to ₹1,756.25 from ₹1,769.57. This reflects updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while staying broadly aligned with recent Street research that has cited better revenue and EBITDA prints, higher guidance, and early benefits from cost actions.Narratiefupdate • Mar 10
NEOGEN: Future P E Compression Will Challenge Optimism Around Cost Driven Margin Gains
Our updated fair value estimate for Neogen Chemicals shifts to ₹1,335 from ₹1,670 as analysts factor in slightly adjusted growth assumptions, a modestly lower discount rate, firmer profit margins and a reduced future P/E multiple, broadly in line with recent Street research that links higher targets in other names to improving revenue quality, cost actions and guidance. Analyst Commentary Street research around Neogen Chemicals points to a more measured setup, even as some peers in the sector see higher optimism baked into targets.Narratiefupdate • Feb 24
NEOGEN: Raised Guidance And Cost Actions Will Support Richer Future Earnings Multiple
Analysts have trimmed their fair value estimate for Neogen Chemicals from ₹1,847 to about ₹1,770, as slightly softer revenue growth and margin inputs are being offset by a higher assumed future P/E multiple and recent Street target hikes following better than expected earnings and guidance. Analyst Commentary Recent Street research around Neogen Chemicals reflects a mix of optimism about execution and some caution on how durable the current momentum might be for earnings and valuation.Narratiefupdate • Feb 10
NEOGEN: Raised Guidance And Cost Actions Will Support Further Upside
Narrative Update: Neogen Chemicals Analysts have lifted their price target on Neogen Chemicals to a range of about $10 to $12, up from $6.50 to $8. This change is attributed to the company’s recent revenue and EBITDA beat, raised guidance, and early benefits from portfolio execution and cost actions.Narratiefupdate • Jan 26
NEOGEN: Raised Guidance And Upcoming Board Results Will Support Upside
Narrative Update The analyst price target for Neogen Chemicals has been adjusted from approximately ₹1,812 to ₹1,847 as analysts factor in recent research that points to steady fair value assumptions, a slightly higher discount rate, unchanged growth and margin inputs, and a modestly higher future P/E multiple in light of recent earnings commentary and guidance updates on Neogen. Analyst Commentary Recent Street research on Neogen Chemicals highlights a mix of optimism around execution and guidance, paired with some restraint on how far the valuation should stretch after the latest earnings release.Narratiefupdate • Jan 09
NEOGEN: Steady Fair Value And Upcoming Results Will Support Upside
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,812.29 per share, with only marginal adjustments to the discount rate, revenue growth, profit margin and future P/E inputs that are too small to materially change the target at this time. What's in the News Board meeting scheduled for November 8, 2025, at 14:30 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narratiefupdate • Dec 26
NEOGEN: Market Perform Initiation Will Support Upside From Resilient Margins
Analysts have modestly revised their price target on Neogen Chemicals upward to $10, reflecting slightly higher long term growth expectations and largely stable margin and valuation assumptions. Analyst Commentary The latest initiation at a Market Perform rating with a $10 price target highlights a balanced view on Neogen Chemicals, with analysts seeing the current valuation as broadly aligned with its near to medium term growth prospects.Narratiefupdate • Dec 11
NEOGEN: Market Perform Initiation Will Support Steady Future Return Potential
Analysts have nudged their price target for Neogen Chemicals slightly higher, reflecting a modest improvement in fair value to roughly ₹1,812 per share. This is supported by expectations of sustained high revenue growth and stable valuation multiples, despite only minor adjustments to discount rate and profit margin assumptions.Analyse-artikel • Dec 04
Why We're Not Concerned Yet About Neogen Chemicals Limited's (NSE:NEOGEN) 26% Share Price Plunge
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has fared very poorly over the last month, falling by a...Narratiefupdate • Nov 27
NEOGEN: Broader Customer Base And Joint Venture Will Support Steady Future Returns
Analysts have maintained Neogen Chemicals' price target at $1,806.57, citing stable growth expectations and aligning their assessment with the recent initiation of a Market Perform rating by the Street. Analyst Commentary Bullish Takeaways Bullish analysts note Neogen Chemicals' consistent revenue growth, which supports the current valuation and underpins the stable price target.Analyse-artikel • Nov 16
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) earnings announcement last week contained some soft numbers, disappointing...Analyse-artikel • Nov 14
Analysts Are More Bearish On Neogen Chemicals Limited (NSE:NEOGEN) Than They Used To Be
One thing we could say about the analysts on Neogen Chemicals Limited ( NSE:NEOGEN ) - they aren't optimistic, having...Narratiefupdate • Nov 12
NEOGEN: Product Diversification Will Drive Long-Term Returns After New Joint Venture
Analysts have revised Neogen Chemicals' fair value target downward from ₹2,062.83 to ₹1,806.57. This adjustment is due to a slightly higher discount rate and moderated revenue growth expectations, as reflected in recent research updates.Analyse-artikel • Nov 11
These 4 Measures Indicate That Neogen Chemicals (NSE:NEOGEN) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narratiefupdate • Aug 06
Expanding Lithium Battery Materials Will Secure Global Reach
Despite an upward revision in revenue growth forecasts, Neogen Chemicals’ consensus price target has been lowered to ₹2,062, primarily due to a substantial decline in its future P/E multiple. What's in the News Annual dividend decreased to INR 1 per share for FY 2024-25.
Nieuw narratief • Mar 15
Merger With BuLi Chemicals Will Strengthen Market Position In Pharma And Agrochemicals
The merger and strategic product expansions aim to strengthen Neogen's market position and boost future export and domestic revenue growth.Analyse-artikel • Feb 21
Neogen Chemicals Limited's (NSE:NEOGEN) P/S Is On The Mark
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...Analyse-artikel • Feb 06
Neogen Chemicals Limited Just Missed Earnings - But Analysts Have Updated Their Models
It's been a pretty great week for Neogen Chemicals Limited ( NSE:NEOGEN ) shareholders, with its shares surging 16% to...Analyse-artikel • Dec 26
Here's Why Neogen Chemicals (NSE:NEOGEN) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Dec 10
The Returns On Capital At Neogen Chemicals (NSE:NEOGEN) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Analyse-artikel • Nov 20
Why Neogen Chemicals' (NSE:NEOGEN) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Neogen Chemicals Limited ( NSE:NEOGEN ) last week didn't sink the stock price...Analyse-artikel • Nov 16
Earnings Miss: Neogen Chemicals Limited Missed EPS By 6.7% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Neogen Chemicals Limited ( NSE:NEOGEN ) released its second-quarter result to the...Analyse-artikel • Sep 20
Investors Appear Satisfied With Neogen Chemicals Limited's (NSE:NEOGEN) Prospects As Shares Rocket 36%
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has done very well over the last month, posting an excellent...Analyse-artikel • May 08
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) recent weak earnings report didn't cause a big stock movement. We think that...Analyse-artikel • May 05
Earnings Miss: Neogen Chemicals Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts
As you might know, Neogen Chemicals Limited ( NSE:NEOGEN ) last week released its latest full-year, and things did not...Analyse-artikel • Apr 26
After Leaping 27% Neogen Chemicals Limited (NSE:NEOGEN) Shares Are Not Flying Under The Radar
Neogen Chemicals Limited ( NSE:NEOGEN ) shares have had a really impressive month, gaining 27% after a shaky period...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | ₹356m |
| Mar 31 2026 | ₹14m | ₹14m | ₹288m |
| Dec 31 2025 | n/a | n/a | ₹197m |
| Sep 30 2025 | n/a | n/a | ₹261m |
| Jun 30 2025 | n/a | n/a | ₹336m |
| Mar 31 2025 | ₹15m | ₹14m | ₹348m |
| Dec 31 2024 | n/a | n/a | ₹494m |
| Sep 30 2024 | n/a | n/a | ₹404m |
| Jun 30 2024 | n/a | n/a | ₹374m |
| Mar 31 2024 | ₹20m | ₹13m | ₹357m |
| Dec 31 2023 | n/a | n/a | ₹330m |
| Sep 30 2023 | n/a | n/a | ₹467m |
| Jun 30 2023 | n/a | n/a | ₹486m |
| Mar 31 2023 | ₹8m | ₹8m | ₹500m |
| Dec 31 2022 | n/a | n/a | ₹513m |
| Sep 30 2022 | n/a | n/a | ₹471m |
| Jun 30 2022 | n/a | n/a | ₹484m |
| Mar 31 2022 | ₹6m | ₹6m | ₹446m |
| Dec 31 2021 | n/a | n/a | ₹383m |
| Sep 30 2021 | n/a | n/a | ₹364m |
| Jun 30 2021 | n/a | n/a | ₹326m |
| Mar 31 2021 | ₹5m | ₹5m | ₹313m |
| Dec 31 2020 | n/a | n/a | ₹293m |
| Sep 30 2020 | n/a | n/a | ₹290m |
| Jun 30 2020 | n/a | n/a | ₹293m |
| Mar 31 2020 | ₹5m | ₹5m | ₹287m |
Compensatie versus markt: De totale vergoeding ($USD 144.38K ) Harin } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 408.91K ).
Compensatie versus inkomsten: De vergoeding van Harin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Harin Kanani (50 yo)
less than a year
Tenure
₹13,750,000
Compensatie
Dr. Harin Haridas Kanani, Ph D serves as the Managing Director of Neogen Chemicals Limited since July 22, 2017 and serves as its Executive Director since July 15, 2013. Dr. Kanani served as Joint Managing...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | less than a year | ₹13.75m | 12.2% ₹ 7.5b | |
| Executive Director & Executive Director of Operation | 2.8yrs | ₹19.52m | 0.0011% ₹ 679.3k | |
| Director of Operations & Whole Time Director | no data | ₹12.35m | 0.00029% ₹ 179.1k | |
| CFO and President Accounts & Finance | 1.9yrs | geen gegevens | geen gegevens | |
| Company Secretary & Compliance Officer | 6.8yrs | ₹690.56k | geen gegevens | |
| Senior General Manager of Marketing | no data | geen gegevens | geen gegevens | |
| President of Human Resources | no data | geen gegevens | geen gegevens | |
| President of New Product Development | 2.9yrs | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NEOGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | 13.2yrs | ₹13.75m | 12.2% ₹ 7.5b | |
| Executive Director & Executive Director of Operation | less than a year | ₹19.52m | 0.0011% ₹ 679.3k | |
| Director of Operations & Whole Time Director | 11.2yrs | ₹12.35m | 0.00029% ₹ 179.1k | |
| Non-Executive Non-Independent Chairman | 9.3yrs | geen gegevens | 0.82% ₹ 507.4m | |
| Chairman Emeritus | less than a year | ₹8.90m | 5.13% ₹ 3.2b | |
| Independent Non-Executive Director | 7.9yrs | ₹1.10m | geen gegevens | |
| Independent Non-Executive Woman Director | 7.9yrs | ₹1.10m | geen gegevens | |
| Independent Director | 2.1yrs | ₹2.40m | 0.0011% ₹ 679.3k | |
| Independent Director | 1.9yrs | ₹2.60m | geen gegevens |
7.9yrs
Gemiddelde duur
65.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NEOGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/10 12:34 |
| Aandelenkoers aan het einde van de dag | 2026/09/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Neogen Chemicals Limited wordt gevolgd door 19 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Asian Markets Securities Private Limited |
| Arun Prasath | Avendus Spark |